PPAR Research

Research Article

The Impact of PPAR Genetic Variants on IBD Susceptibility and IBD Disease Course

Table 9

Haplotype and diplotype distribution in IBD cases with and without EIMs.
Subjects includedH1 (CC)H2 (CT)H3 (GC)H4 (GT)
IBD N (%) 110189.8 (86.2)10.2 (4.6)3.2 (1.5)16.8 (7.6) 0.57
OR (CI)1.18 (0.72–1.95)1.18 (0.50–2.80)0.44 (0.12–1.58)0.87 (0.46–1.67)
Controls(b)143240.7 (84.1)11.4 (4.0)9.3 (3.3)24.7 (8.6)
UC N (%) 4576.9 (85.5)5.1 (5.6)1.1 (1.2)6.9 (7.7) 0.55
OR (CI)1.15 (0.56–2.37)1.79 (0.51–6.25)0.36 (0.04–2.93)0.76 (0.3–1.93)
Controls(b)80133.8 (83.6)5.2 (3.2)5.2 (3.2)15.8 (9.9)
CD N (%) 65112.8 (86.8)5.2 (4.0)2.2 (1.7)9.8 (7.6) 0.82
OR (CI)1.18 (0.58–2.38)0.8 (0.24–2.66)0.49 (0.09–2.61)1.09 (0.42–2.79)
Controls(b)63106.8 (84.8)6.2 (4.9)4.2 (3.3)8.8 (7.0)
D1 (CC/CC)D2 (CC/GT)D3 (CC/GC)D4 (CC/CT)
IBD N (%) 11082.0 (74.5)14.8 (13.4)3.0 (2.7)8.0 (7.3)
OR (CI)1.30 (0.75–2.27)0.82 (0.41–1.67)0.42 (0.11–1.58)0.94 (0.37–2.43)
Controls(b)14399.0 (69.2)22.7 (15.8)9.0 (6.3)11.0 (7.7)
UC N (%) 4533.0 (73.3)(13.2)1.0 (2.2)4.0 (8.9)
OR (CI)1.25 (0.55–2.82)0.73 (0.26–2.06)0.34 (0.04–3.01)1.46 (0.37–5.75)
Controls(b)8055.0 (68.8)13.8 (17.3)5.0 (6.3)5.0 (6.3)
CD N (%) 6549.0 (75.4)8.8 (13.6)2.0 (3.1)4.0 (6.2)
OR (CI)1.32 (0.61–2.88)0.96 (0.35–2.63)0.47 (0.08–2.65)0.62 (0.17–2.32)
Controls(b)6344.0 (69.8)8.8 (14.0)4.0 (6.3)6.0 (9.5)
D5 (CT/GT)D6 (GC/GT)D7 (GC/CT)D8 (GT/GT)
IBD N (%)2.0 (1.8) NP NP0.0 (0)0.36
OR (CI)——
Controls0.0 (0)NPNP1.0 (0.7)
UC N (%)1.0 (2.2) NP NP0.0 (0)0.6
OR (CI)——
Controls0.0 (0)NPNP1.0 (1.3)
CD N (%)1.0 (1.5) NP NP NP0.73
OR (CI)—
Controls0.0 (0)NPNPNP
OR: odds ratio; CI: confidence interval; N: absolute number; H1–H4: haplotype 1—haplotype 4; D1–D8: diplotype 1—diplotype 8; EIMs: extraintestinal manifestations; NP: predicted not to appear in the case or control group; (a) values calculated with FAMHAP; (b)the term “controls” denotes here the respective patient subgroup (IBD/UC/CD) without EIMs.